Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats

Kae Matsuura¹,², Atsushi Sakai² , Yuji Watanabe², Yasunori Mikahara², Atsuhiro Sakamoto¹, and Hidenori Suzuki² 

Abstract
Oxaliplatin, a platinum-based chemotherapeutic agent, frequently causes severe neuropathic pain typically encompassing cold allodynia and long-lasting mechanical allodynia. Endothelin has been shown to modulate nociceptive transmission in a variety of pain disorders. However, the action of endothelin varies greatly depending on many variables, including pain causes, receptor types (endothelin type A (ETA) and B (ETB) receptors) and organs (periphery and spinal cord). Therefore, in this study, we investigated the role of endothelin in a Sprague–Dawley rat model of oxaliplatin-induced neuropathic pain. Intraperitoneal administration of bosentan, a dual ETA/ETB receptor antagonist, effectively blocked the development or prevented the onset of both cold allodynia and mechanical allodynia. The preventive effects were exclusively mediated by ETA receptor antagonism. Intrathecal administration of an ETA receptor antagonist prevented development of long-lasting mechanical allodynia but not cold allodynia. In marked contrast, an intraplantar ETA receptor antagonist had a suppressive effect on cold allodynia but only had a partial and transient effect on mechanical allodynia. In conclusion, ETA receptor antagonism effectively prevented long-lasting mechanical allodynia through spinal and peripheral actions, while cold allodynia was prevented through peripheral actions.

Keywords
ET-1, ET receptor, spinal cord, periphery, neuropathic pain

Introduction
Oxaliplatin is a third-generation platinum-based chemotherapeutic agent and is a key drug used to treat advanced colorectal cancer. However, oxaliplatin causes peripheral neuropathy in approximately 80%–90% of patients.¹,² The most common symptom is cold allodynia in the hands and feet, which generally disappears within a few hours or days of treatment.³ In addition, approximately 10%–30% of patients suffer from long-lasting neuropathy such as pain and paresthesia,¹,²,⁴ which are dose-limiting adverse effects that reduce the effect of anti-cancer therapy because of oxaliplatin dose reduction or cessation. In addition, long-lasting, oxaliplatin-induced neuropathy may persist longer than 12 months, even with reduction or discontinuation of oxaliplatin treatment.¹,²,⁵ However, existing analgesic drugs (e.g., duloxetine and pregabalin) and non-pharmacological treatments have limited effects against pain related to...
oxaliplatin-induced persistent neuropathy. Therefore, a therapeutic approach to prevent the development of oxaliplatin-induced neuropathy is expected to improve patient quality of life as well as cancer treatment.

Endothelin-1 (ET-1), a 21-amino acid peptide transmitter, is ubiquitously expressed and involved in a variety of physiological and pathological processes. ET-1 acts through two cognate receptors, endothelin type A (ET\(_A\)) and B (ET\(_B\)) receptors, both of which are involved in pain processing, apart from their vascular actions, in both the periphery and spinal cord. In the periphery, ET-1 has been repeatedly shown to cause mechanical allodynia observed in a variety of pain conditions through ET\(_A\) receptors. However, the role of ET\(_B\) receptors in pain is more varied. In the spinal cord, the effect of ET-1 on nociceptive transmission is poorly understood. Intrathecal administration of an ET\(_A\) receptor antagonist has been shown to inhibit spinal nerve ligation (SNL)-induced neuropathic pain and spinal cord injury-induced mechanical allodynia. In contrast, intrathecal application of ET-1 induces ET\(_A\) receptor-mediated analgesia against incision-induced pain and neuropathic pain caused by sciatic nerve ligation. Similarly, intrathecal administration of an ET\(_B\) receptor antagonist exerted an antinociceptive effect on SNL-induced mechanical allodynia but blocked the anti-nociceptive effect of spinal ET-1 on incision-induced pain and had no effect on spinal cord injury-induced mechanical allodynia. Thus, the function of ET-1 in the regulation of nociception seems dependent on the receptor type (ET\(_A\) and ET\(_B\)), pain condition and site of action (periphery or spinal cord), although ET-1 signaling is a plausible target to treat pain disorders. Interestingly, oxaliplatin was reported to increase ET\(_A\) receptor expression in the spinal cord and ET\(_A\) and ET\(_B\) receptor expression in the dorsal root ganglion (DRG). In addition, intraplantar administration of an ET\(_A\) or ET\(_B\) receptor antagonist partially suppressed mechanical allodynia. However, the role of ET\(_A\) and ET\(_B\) receptors in the spinal cord in oxaliplatin-induced neuropathic pain remains unknown. Therefore, in this study, we used endothelin receptor antagonists to investigate the role of ET-1 in the development of oxaliplatin-induced cold allodynia and long-lasting mechanical allodynia, especially focusing on the site of action and receptor types.

Materials and methods

Experimental animals

Male Sprague–Dawley rats (6–7 weeks; 180–230 g; Sankyo Labo Service Corporation, Tokyo, Japan) were used. Rats were housed individually with lights on from 06:00 to 20:00 h at room temperature (23 ± 1°C). Animals had free access to water and food in their home cages. All experimental procedures were performed in agreement with the procedures set by the institution’s Animal Experiments Ethical Review Committee and were previously approved by the President of Nippon Medical School (Approval number 27-037). To observe the effect of intrathecal atrasentan administration on body temperature, the body temperature (rectal and surface of the hind paw pad) was measured using a digital thermometer or non-contact infrared thermometer before (day −1) and after (day 7) intrathecal atrasentan administration.

Drug administration

Oxaliplatin (Yakult Corporation, Tokyo, Japan) was diluted in 5% glucose solution (1 mg/mL) and intraperitoneally administered at a dose of 5 mg/kg at day 0. Bosentan, a dual ET\(_A\)/ET\(_B\) receptor antagonist (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan), atrasentan, a selective ET\(_A\) receptor antagonist (Sigma-Aldrich, St Louis, MO, USA) and BQ-788, a selective ET\(_B\) receptor antagonist (Alomone Labs, Jerusalem, Israel) were dissolved in 60% dimethylsulfoxide and 40% propylene glycol. Bosentan was intraperitoneally administered for 8 consecutive days (5, 15, or 50 mg/kg per day from days −1 to 6). Atrasentan (1, 3, or 10 mg/kg per day) was intraperitoneally administered for 2 consecutive days (days −1 and 0). BQ-788 was intraperitoneally administered at a dose of 1 mg/kg for 2 consecutive days (days −1 and 0). On day 0, bosentan, atrasentan and BQ-788 were administered immediately after oxaliplatin treatment. For peripheral administration, atrasentan was injected into the hind paw at a dose of 40 μg in 40 μL of solution 30 min before oxaliplatin administration. An equivalent volume of vehicle was administered as a control.

An intrathecal catheter was inserted for drug administration in the rats 2–3 days before oxaliplatin administration, as previously described. Briefly, a polyethylene catheter (PE-10) filled with saline was inserted into the spinal subarachnoid space to the level of the L4–5 enlargement of the spinal cord under 2–3% isoflurane anesthesia. Rats with neurological symptoms such as paralysis or dysesthesia of the hind legs after catheterization were excluded. Intrathecal administration of atrasentan or BQ-788 was delivered at a dose of 50 μg in 10 μL of solution, followed by injection of an additional 10 μL of saline, using a 10-μL Hamilton microsyringe, into the intrathecal catheter for 2 consecutive days from day 1 prior to oxaliplatin administration.

Evaluation of allodynia

We used a von Frey test to observe the response to mechanical stimuli. Rats were placed in a plastic box with a wire mesh floor and allowed to habituate for 15 min prior to testing. von Frey filaments (Muromachikikai, Tokyo, Japan) with bending forces ranging between 2 and 16 g were applied to the midplantar skin of the left hind paw from underneath the mesh floor, with each application held for 10 s. The test was started with the filament with the lightest bending force applied for five consecutive times, followed by stimulation with the next filament. The force of the first filament that elicited three positive paw withdrawal responses in five applications was recorded as the paw withdrawal threshold.
To observe the response to cold stimuli, an acetone test was performed. Rats were placed in a plastic box with a wire mesh floor and allowed to habituate for 15 min prior to testing. Using a 0.5 mL syringe with a 26 G needle, acetone was applied to the ventral side of one hind paw from underneath the mesh floor, and the rat’s response was monitored, as previously described.29 Briefly, rats were first evaluated for 20 s. If the rat did not respond within 20 s, the result was recorded as no response. However, if the rat responded within the initial 20 s, the rat was monitored for an additional 40 s (a total observation period of 1 min from the initial application). Acetone was applied alternately twice to each hind paw, with a 5-min interval between applications. Responses were graded according to a 4-point scale, as previously described10, 0, no response; 1, quick withdrawal, flick or stamp of the paw; 2, prolonged withdrawal or repeated flicking of the paw with persistent licking directed at the ventral side of the paw. Cumulative scores were obtained by summing the points of four trials (two for each paw) with a minimum score of 0 (no response to any of the four trials) and a maximum score of 12 (repeated flicking and licking of paws in all four trials). The acetone and von Frey tests were performed on different animals. Behavioral tests were performed in a manner blinded to ET-1 antagonist treatment.

Open field test
An open field test was performed 7 days after intrathecal atrasentan administration. The open field consisted of an opaque black plastic board (100 cm × 100 cm) with walls (50 cm in height). Each rat was placed at the corner of the open field, and the behavior was recorded for 10 min using a CCD camera. The total distance travelled in the open field and the time spent in the center zone of the open field (defined as the central 60 cm × 60 cm area) were analyzed using ImageJ software (ImageJ OF; O’Hara and Co., Ltd., Tokyo, Japan).

Quantitative polymerase chain reaction
The L4 DRG and L5 dorsal spinal cord were removed 24 h after oxaliplatin administration, frozen in liquid nitrogen and stored at −80°C until RNA purification was performed. Total RNA was extracted using RNAiso plus (Takara Bio, Shiga, Japan). The total RNA (500 ng) was reverse-transcribed with random primers using an iScript Select cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). Quantitative PCR was performed using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) on a QuantStudio 3 Real-time PCR System (Thermo Fisher Scientific). The PCR program was initiated at 95°C for 10 min, followed by 40 cycles consisting of 95°C for 15 s and 60°C for 1 min. Primer pairs for ETₐ and ETₐ receptors were designed using Primer blast (https://www.ncbi.nlm.nih.gov/) as the following sequences: ETₐ receptor (forward, 5'-AACCTGGCAACATGAACTCT-3' and reverse, 5'-GGACTGGTGACACAGCAAC-3') and ETₐ receptor (forward, 5'-GAGTCCCGCAAGATCCTTC-3' and reverse, 5'-TTCCCGATGATGCCTAGCAC-3'). All samples were measured in triplicate.

Statistical analysis
von Frey and acetone test data are presented as the mean ± SEM and as the median, minimum, maximum and interquartile range values in box plot graphs, respectively. Because normality of the data was not assumed by the Shapiro–Wilk test (SPSS software, version 25; IBM, Chicago, IL, USA), the Mann–Whitney U-test was used for statistical analysis using SPSS software. For dose–response effects, the Steel test was used for statistical analysis using KyPlot (version 6.0.2, KyenceLab, Tokyo, Japan). A p value of <0.05 was considered significant.

Results
Oxaliplatin induced long-lasting mechanical allodynia and cold allodynia
To clearly distinguish between long-lasting mechanical allodynia and cold allodynia, a single dose of oxaliplatin was given on day 0. The paw withdrawal threshold was significantly decreased from 2 h after oxaliplatin administration and persisted for at least 14 days (Figure 1(a)), indicating that mechanical allodynia persisted long after oxaliplatin administration. In contrast, the response score for acetone application was increased only for 4 days (Figure 1(b)), indicating cold allodynia.

Systemic administration of a dual ETₐ/ETₐ receptor antagonist prevented both mechanical allodynia and cold allodynia induced by oxaliplatin
To examine the preventive effect of an endothelin receptor antagonist on oxaliplatin-induced neuropathic pain, a dual ETₐ/ETₐ receptor antagonist, bosentan, was intraperitoneally administered once a day from 1 day before to 6 days after oxaliplatin injection (8 consecutive days). Pre-emptive systemic treatment with bosentan (50 mg/kg) blocked the decrease in the paw withdrawal threshold induced by oxaliplatin for at least 11 days compared with vehicle treatment (Figure 2(a)). The analgesic effect of bosentan at day 1 after oxaliplatin administration was dose-dependent (Figure 2(b)). The increase in the response score for acetone application was also blocked by intraperitoneal bosentan treatment, compared with the vehicle treatment (Figure 2(c)). Thus, endothelin receptor antagonism effectively prevented the development of mechanical allodynia and cold allodynia induced by oxaliplatin administration. Next, we examined ETₐ and ETₐ receptor expression in the DRG and dorsal spinal cord. The ETₐ and ETₐ receptor mRNA expression levels were unchanged in the L4 DRG and dorsal spinal cord 1 day after oxaliplatin administration (Supplemental Figure 1(a, b)). Additionally, pre-emptive systemic treatment with bosentan did not change the
ETα and ETβ receptor mRNA expression levels in the L4 DRG and dorsal spinal cord (Supplemental Figure 1(c, d)).

**Inhibition of ETα receptors, but not ETβ receptors, prevented oxaliplatin-induced mechanical allodynia and cold allodynia**

To investigate whether the ETα or ETβ Receptor is involved in oxaliplatin-induced neuropathic pain, an ETα receptor-selective antagonist, atrasentan, and an ETβ receptor-selective antagonist, BQ-788, were intraperitoneally administered for 2 consecutive days from 1 day before oxaliplatin administration. Pre-emptive systemic atrasentan treatment blocked oxaliplatin-induced mechanical allodynia for 28 days compared with vehicle treatment (Figure 3(a)). The analgesic effect of atrasentan at day 1 after oxaliplatin administration was dose-dependent (Figure 3(b)). Cold allodynia was also prevented by systemic atrasentan administration (Figure 3(c)). In marked contrast, BQ-788 did not have any effect on mechanical allodynia or cold allodynia.
cold allodynia throughout the observation period (Figure 3(d, e)).

**Oxaliplatin-induced long-lasting mechanical allodynia, but not cold allodynia, was mediated by spinal ET<sub>A</sub> receptors**

Because ET<sub>A</sub> receptor signaling has been shown to modulate nociceptive processing through both the spinal cord and periphery, we first investigated the involvement of spinal ET<sub>A</sub> receptors in oxaliplatin-induced neuropathic pain. Intrathecal administration of atrasentan for 2 consecutive days from 1 day prior to oxaliplatin administration prevented the development of mechanical allodynia for 28 days (Figure 4(a)). In marked contrast, cold allodynia was not prevented by intrathecal atrasentan administration (Figure 4(b)). Furthermore, intrathecal administration of BQ-788 for 2 consecutive days, from 1 day prior to oxaliplatin administration, did not have any effect on mechanical allodynia or cold allodynia throughout the observation period (Figure 4(c, d)). Intrathecal administration of atrasentan did not cause significant changes in locomotor activity and time spent in the center in the open field test on day 7 after oxaliplatin administration (Supplemental Figure 2(a), (b)). Intrathecal administration of an ET<sub>A</sub> receptor antagonist before oxaliplatin administration also had no effect.
Figure 4. Intrathecal administration of an ETA receptor antagonist prevented oxaliplatin-induced mechanical allodynia but not cold allodynia: Mechanical allodynia (a, c) and cold allodynia (b, d) were examined using the von Frey test and the acetone test, respectively. Atrasentan (50 μg) or BQ-788 (50 μg) was intrathecally administered for 2 consecutive days (days 1 and 0) before intraperitoneal oxaliplatin administration (5 mg/kg) on day 0 (n = 5–6). (a, c) Mechanical allodynia was examined before each drug administration and 2 h, 8 h, 24 h, 4 days, 7 days, 11 days, 14 days, 21 days, and 28 days after oxaliplatin administration. (b, d) Cold allodynia was examined before atrasentan, BQ-788 and oxaliplatin administration and 2 h, 8 h and 24 h after oxaliplatin administration. * p < 0.05, ** p < 0.01 and *** p < 0.001, compared with the vehicle group using the Mann–Whitney U-test. Pre: before administration of atrasentan or BQ-788.

Figure 5. Intraplantar administration of an ETA receptor antagonist prevented oxaliplatin-induced cold allodynia and temporarily suppressed mechanical allodynia: Mechanical allodynia (a) and cold allodynia (b) were examined using the von Frey test and the acetone test, respectively. Atrasentan was intraplantarly administered to the left midplantar paw (a) and to both midplantar paws (b) at 30 min before intraperitoneal oxaliplatin administration. In the control group, an equivalent volume of vehicle was intraplantarly administered (n = 5–6). Mechanical allodynia was examined before atrasentan and oxaliplatin administration and 2 h, 8 h, 24 h, and 4 days after oxaliplatin administration. Cold allodynia was examined before atrasentan and oxaliplatin administration and 2 h, 8 h, 24 h, and 4 days after oxaliplatin administration. * p < 0.05 and ** p < 0.01, compared with the vehicle group using the Mann–Whitney U-test. Pre: before administration of atrasentan.
Peripheral ET\textsubscript{A} receptors mainly mediated oxaliplatin-induced cold allodynia

We further explored the involvement of peripheral ET\textsubscript{A} receptors in oxaliplatin-induced neuropathic pain. To examine the effects on mechanical allodynia and cold allodynia, atrasentan was intraplantarly administered to the left mid-plantar paw and to both sides of the midplantar paws, respectively, 30 min before oxaliplatin administration. Intraplantar administration of the ET\textsubscript{A} receptor antagonist partially inhibited mechanical allodynia only for 1 day after oxaliplatin administration (Figure 5(a)). However, cold allodynia induced by oxaliplatin was effectively blocked by intraplantar atrasentan administration (Figure 5(b)).

Discussion

We first showed that pre-emptive inhibition of ET\textsubscript{A} receptors in the spinal cord effectively prevented the development of oxaliplatin-induced mechanical allodynia but not cold allodynia. In marked contrast, pre-emptive inhibition of ET\textsubscript{A} receptors in the periphery blocked cold allodynia but only partially and transiently alleviated mechanical allodynia. Therefore, through multiple sites of action, the ET\textsubscript{A} receptor antagonist effectively prevented the development of long-lasting mechanical allodynia and cold allodynia in oxaliplatin-induced neuropathic pain.

Spinal ET\textsubscript{A} receptors are involved in the development of oxaliplatin-induced mechanical allodynia

ET-1/ET\textsubscript{A} signaling in the spinal cord contributes to the development of oxaliplatin-induced long-lasting mechanical allodynia. Systemic and intrathecal administration of an ET\textsubscript{A} receptor antagonist, atrasentan, had a long-lasting suppressive effect on mechanical allodynia. However, the suppressive effects of the dual ET\textsubscript{A}/ET\textsubscript{B} receptor antagonist bosentan on mechanical allodynia disappeared at day 14. The shortened effect of the dual ET\textsubscript{A}/ET\textsubscript{B} receptor antagonist may be caused by the interfering effect of ET\textsubscript{B} receptor antagonism on the analgesic effect of the ET\textsubscript{A} receptor antagonist.\textsuperscript{26} In fact, inhibition of ET\textsubscript{B} receptors has been shown to promote the effects of endothelin.\textsuperscript{11,13,14} Regarding the preventive effect of the ET\textsubscript{A} receptor antagonist on mechanical allodynia in the long term, spinal ET\textsubscript{A} signaling may be involved in the induction of long-lasting mechanical allodynia. In fact, central sensitization in the spinal cord is a well-known basis for chronic pain that continues even after the initial cause has dissipated.\textsuperscript{31} Spinal glutamatergic transmission and NMDA receptor function, which are critical mediators of central sensitization, were reportedly upregulated in oxaliplatin-induced mechanical allodynia.\textsuperscript{32,33} Although ET\textsubscript{A} receptor expression has been shown in spinal neurons\textsuperscript{13} and vascular smooth muscle cells,\textsuperscript{9} the mechanisms underlying the pronociceptive effect of ET\textsubscript{A} receptor activation in these cells remain mostly unknown. However, ET-1 expression has been reported in various spinal cells, including neurons,\textsuperscript{17} astrocytes,\textsuperscript{34} and microglia.\textsuperscript{17} Astrocytes\textsuperscript{35,36} and microglia\textsuperscript{37} were shown to be activated in oxaliplatin-induced neuropathy, while it has also been reported that they were not activated by oxaliplatin.\textsuperscript{38} Increased production of pro-inflammatory cytokines (tumor necrosis factor \(\alpha\) and interleukin-1\(\beta\)) in spinal astrocytes reportedly contributes to oxaliplatin-induced mechanical allodynia.\textsuperscript{35,36} However, penetration of systemically administered oxaliplatin into the central nervous system is limited because of its poor ability to cross the blood–brain barrier,\textsuperscript{39} indicating that ET-1 signaling in the spinal dorsal horn may be mediated by indirect action of oxaliplatin on the spinal cord. In contrast, ET\textsubscript{A} receptor expression was unchanged in both the DRG and dorsal spinal cord early after oxaliplatin administration, while it was increased in the DRG and dorsal spinal cord of mice 28 days after initiation of oxaliplatin administration twice a week.\textsuperscript{13} These results suggest that the role of ET-1 differs between the acute and chronic phases of oxaliplatin-induced neuropathic pain. Overall, ET-1/ET\textsubscript{A} receptor-mediated central sensitization in the spinal dorsal horn may contribute to the development of oxaliplatin-induced mechanical allodynia. In contrast to oxaliplatin-induced mechanical allodynia, cold allodynia was not blocked by spinal inhibition of ET\textsubscript{A} receptors. Considering that spinal processing of nociception is distinct among modalities of nociceptive stimuli,\textsuperscript{40,41} ET\textsubscript{A} receptors in the spinal cord are thought to be specifically involved in the regulation of mechanical pain after oxaliplatin treatment.

ET\textsubscript{A} receptors in the spinal cord may also be involved in the mechanical allodynia observed in other types of chemotherapy-induced neuropathy. Cisplatin, another platinum derivative, also induces mechanical allodynia, which is thought to be partly mediated by a shared mechanism with oxaliplatin.\textsuperscript{23,42} Because neuropathy induced by other chemotherapeutics, such as taxanes, also causes mechanical allodynia and spinal sensitization\textsuperscript{42} through shared and distinct mechanisms,\textsuperscript{43} investigating the role of ET\textsubscript{A} in other types of chemotherapy-induced neuropathic pain will provide further insight into the mechanisms of chemotherapy-induced peripheral neuropathy.

Peripheral ET\textsubscript{A} receptors are critical for oxaliplatin-induced cold allodynia

ET-1/ET\textsubscript{A} receptor signaling in the periphery was only partially involved in mechanical allodynia, consistent with a previous report.\textsuperscript{11} However, we found that an ET\textsubscript{A} receptor antagonist effectively suppressed oxaliplatin-induced cold allodynia. Thus, our findings suggest that mechanical
alldynia and cold allodynia are differentially mediated in the periphery by ET$_A$ receptors, which is consistent with evidence that different oxaliplatin metabolites, oxalate and dichloro(1,2-diaminocyclohexane)platinum (Pt(dach)Cl$_2$), contribute to cold allodynia and mechanical allodynia, respectively. ET-1 has been shown to be produced by vascular endothelial cells and keratinocytes in the periphery and pro-inflammatory cytokine stimulation, respectively. In fact, these non-neural cells were recently suggested to contribute to nociception, in addition to DRG neurons. ET-1 directly activates ET$_A$ receptors in nociceptive DRG neurons to modulate nociception. For example, ET-1 was reported to enhance tetrodotoxin-resistant sodium currents, sensitize TRPV1 and TRPA1 receptors to noxious thermal stimuli and induce release of neurotransmitters, glutamate, substance P, and CGRP. Therefore, oxaliplatin may stimulate ET-1 release from non-neuronal cells in the periphery, leading to indirect ET$_A$ receptor activation at the peripheral axon terminal of nociceptive DRG neurons to produce cold alldynia and mechanical allodynia.

Neither oxaliplatin-induced mechanical alldynia nor cold allodynia were suppressed by systemic administration of an ET$_B$ receptor antagonist

In the present study, systemic administration of a selective ET$_B$ receptor antagonist had no obvious effect on oxaliplatin-induced neuropathic pain in rats, although administration of an ET$_B$ receptor antagonist in the peripheral tissue was previously shown to partially inhibit oxaliplatin-induced mechanical alldynia in mice. This discrepancy in ET$_B$ receptor action may be caused by a difference of animal species. Alternatively, ET$_B$ receptor inhibition at a site other than peripheral tissues may counteract the analgesic effect of peripheral ET$_B$ receptor antagonism. In fact, ET$_B$ receptor activation has both pronociceptive and anti-nociceptive effects in both the spinal cord and periphery. Intrathecal administration of an ET$_B$ receptor antagonist temporarily suppressed SNL-induced mechanical alldynia in rats while also suppressing the anti-nociceptive effect of ET-1 on postoperative pain in rats. Intraplantar administration of an ET$_B$ receptor antagonist prevented oxaliplatin-induced and carrageenan/complete Freund’s adjuvant-induced mechanical allodynia in mice. In contrast, intraplantar administration of an ET$_B$ receptor antagonist enhanced flinching behavior induced by ET-1 in naïve rats. Therefore, ET$_B$ receptor-mediated modulation of nociception seems dependent on its site of action, the cause of pain or differences in experimental animal species. In addition to these causes of variation, sex differences in endothelin function may exist. The role of neuroendocrine stress axes in oxaliplatin-induced peripheral neuropathy was shown to be sexually dimorphic, although the overall severity was not. The effect of ET-1 was also reported to be sexually dimorphic in the control of vascular tone but not in the control of the renal microvasculature. Sex or sex hormones evoked different types of ET-1 control on vascular tone.

In conclusion, our present study showed that through peripheral and spinal effects, an ET$_A$ receptor antagonist effectively prevented both cold allodynia and long-lasting mechanical allodynia, which is frequently observed as a dose-limiting adverse effect of oxaliplatin. These results may suggest that administration of an ET$_A$ receptor antagonist prior to oxaliplatin administration may be useful to pre-empt the neuropathic effects of this chemotherapeutic agent. Therefore, elucidating the role of ET$_A$ receptors in oxaliplatin-induced neuropathic pain is expected to lead to the development of new therapeutic strategies.

Author contributions

KM, AS, and HS designed the study. KM, AS, YM, and YW conducted the experiments. KM, AS, AS, and HS analyzed the data, prepared the figures, and wrote the manuscript. All authors have approved the final manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article. This work was supported by the Japan Society for the Promotion of Science KAKENHI (grant numbers: JP16H05461 and JP19H03552).

ORCID iDs

Atsushi Sakai https://orcid.org/0000-0002-3996-8022
Hidenori Suzuki https://orcid.org/0000-0002-7133-4302

Supplemental Material

Supplemental material for this article is available online.

References

1. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–2351.
2. Yoshino T, Kotaka M, Shinozaki K, et al. Join trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer. Cancer Chemother Pharmacol 2019; 84: 1269–1277.
3. Wilson RH, Lehky T, Thomas RR, et al Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20: 1767–1774.
4. Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-
year colorectal cancer survivors: results from the population-based registry. *J Clin Oncol* 2013; 31: 2699–2707.
5. de Gramont A, Figar A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2000; 18: 2938–2947.
6. Flatters SJL, Dougherty PM and Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. *Br J Anaesth* 2017; 119: 737–749.
7. Cavaletti G, Marmiroli P. Management of oxaliplatin-induced peripheral sensory neuropathy. *Cancers (Basel)* 2020; 12: 1370.
8. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. *Nat Rev Cardiol* 2016; 68: 357–418.
9. Dhaun N and Webb DJ. Endothelins in cardiovascular biology and therapeutics. *Nat Rev Cardiol* 2019; 16: 491–502.
10. Enevoldsen FC, Sahana J, Wehland M, et al. Endothelin receptor antagonists: status quo and future perspectives for targeted therapy. *J Clin Med* 2020; 9: 824.
11. Khodorova A, Montmayeur JP, Strichartz G. Endothelin receptors and pain. *J Pain* 2009; 10: 4–28.
12. Smith TP, Haymond T, Smith SN, et al. Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. *J Pain Res* 2014; 7: 531–545.
13. Pontes RB, Lisboa MRP, Pereira AF, et al. Involvement of endothelin receptors in peripheral sensory neuropathy induced by oxaliplatin in mice. *Neurotox Res* 2019; 36: 688–699.
14. Khodorova A, Fareed MU, Gokin A, et al. Local injection of a selective endothelin-B receptor agonist inhibits endothelin-1-induced pain-like behavior and excitation of nociceptors in a naloxone-sensitive manner. *J Neurosci* 2002; 22: 7788–7796.
15. Buamonde A, Lastra A, Villazon M, et al. Involvement of endogenous endothelins in thermal and mechanical inflammatory hyperalgesia in mice. *Naunyn Schmiedebergs Arch Pharmacol* 2004; 369: 245–251.
16. Tai LW, Hung VK, Mei W, et al. Effects of repeated central administration of endothelin type A receptor antagonist on the development of neuropathic pain in rats. *Biomed Res Int* 2013; 2013: 529871.
17. Tai LW, Pan Z, Sun L, et al. Suppression of Pax2 attenuates allodynia and hyperalgesia through ET-1-ETAR-NFAT5 signaling in a rat model of neuropathic pain. *Neuroscience* 2018; 384: 139–151.
18. Forner S, Martini AC, Andrade EL, et al. Neuropathic pain induced by spinal cord injury: role of endothelin ET\(_A\) and ET\(_B\) receptors. *Neurosci Lett* 2016; 617: 14–21.
19. Chen G, Tanabe K, Yanagidate F, et al. Intrathecal endothelin-1 has antinociceptive effects in rat model of postoperative pain. *Eur J Pharr* 2012; 697: 40–46.
20. Hung VK, Tai LW, Qiu Q, et al. Over-expression of astrocytic ET-1 attenuates neuropathic pain by inhibition of ERK1/2 and Akt(s) via activation of ETA receptor. *Mol Cell Neurosci* 2014; 60: 26–35.
21. Kim YO, Kim IJ and Yoon MH. Antiallodynic effect through spinal endothelin-B receptor antagonism in rat models of complex regional pain syndrome. *Neurosci Lett* 2015; 584: 45–49.
22. Zhao M, Isami K, Nakamura S, et al. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRP\(_A\) in mice. *Mol Pain* 2012; 8: 55.
23. Joseph EK and Levine JD. Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. *J Pain* 2009; 10: 534–541.
24. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. *J Phar Exp Ther* 1994; 270: 228–235.
25. Biein S, Riad A, Ritter CA, et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. *Cancer Res* 2007; 67: 10428–10435.
26. Jarvis MF, Wessale JL, Zhu CZ, et al. ABT-627, an endothelin ET\(_A\) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. *Eur J Pharr* 2000; 388: 29–35.
27. Ishikawa K, Ibara M, Naguchi K, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. *Proc Natl Acad Sci USA* 1994; 91: 4892–4896.
28. Yaksh TL and Rudy TA. Chronic catheterization of the spinal subarachnoid space. *Physiol Behav* 1976; 17: 1031–1036.
29. Flatters SJL and Bennett GJ. Ethosuximide reverses paelitaxel- and vincristine-induced painful peripheral neuropathy. *Pain* 2004; 109: 150–161.
30. Bardin L, Malfetes N, Newman-Tancredi A, et al. Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies. *Behav Brain Res* 2009; 205: 360–366.
31. Latremoliere A and Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. *J Pain* 2009; 10: 895–926.
32. Mihaia Y, Egashira N, Sada H, et al. Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats. *Mol Pain* 2011; 7: 8.
33. Yamamoto S, Uschio S, Egashira N, et al. Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. *Sci Rep* 2017; 7: 9661.
34. Ranno E, D’Antoni S, Spatuzza M, et al. Endothelin-1 is over-expressed in amyotrophic lateral sclerosis and induces motor neuron cell death. *Neurobiol Dis* 2014; 65: 160–171.
35. Yoon SY, Robinson CR, Zhang H, et al. Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. *J Pain* 2013; 14: 205–214.
36. Janes K, Wahlman C, Little JW, et al. Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A\(_3\) adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. *Brain Behav Immun* 2015; 44: 91–99.
37. Kim ST, Chung YH, Lee HS, et al. Protective effects of phosphatidylcholine on oxaliplatin-induced neuropathy in rats. *Life Sci* 2015; 130: 81–87.
38. Makker PGS, Duffy SS, Lees JG, et al. Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy. *PLoS One* 2017; 12: e0170814.

39. Jacobs SS, Fox E, Dennie C, et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. *Clin Cancer Res* 2005; 11: 1669–1674.

40. Peris C and Seal RP. Neural circuits for pain: recent advances and current views. *Science* 2016; 354: 578–584.

41. Petitjean H, Bouroujeni FB, Tsao D, et al. Recruitment of spino-parabrachial neurons by dorsal horn calretinin neurons. *Cell Rep* 2019; 28: 1429–1438.

42. Kerckhove N, Collin A, Condé S, et al. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. *Front Pharmacol* 2017; 8: 86.

43. Yamamoto S and Egashira N. Drug repositioning for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a mechanism- and screening-based strategy. *Front Pharmacol* 2021; 11: 607780.

44. Sakurai M, Egashira N, Kawashiri T, et al. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. *Pain* 2009; 147: 165–174.

45. Corder R, Carrier M, Khan N, et al. Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells. *J Cardiovasc Pharmacol* 1995; 26: 56–58.

46. Tsuboi R, Sato C, Oshita Y, et al. Ultraviolet B irradiation increases endothelin-1 and endothelin receptor expression in cultured human keratinocytes. *FEBS Lett* 1995; 371: 188–190.

47. Ehrenreich H, Costa T, Clouse KA, et al. Thrombin is a regulator of astrocytic endothelin-1. *Brain Res* 1993; 600: 201–207.

48. Talagas M, Lebonvallet N, Berthod F, et al. Lifting the veil on the keratinocyte contribution to cutaneous nociception. *Protein Cell* 2020; 11: 239–250.

49. Joseph EK, Green PG and Levine JD. ATP release mechanisms of endothelial cell-mediated stimulus-dependent hyperalgesia. *J Pain* 2014; 15: 771–777.

50. Joseph EK, Green PG, Bogen O, et al. Vascular endothelial cells mediate mechanical stimulation-induced enhancement of endothelin hyperalgesia via activation of P2X_{2/3} receptors on nociceptors. *J Neurosci* 2013; 33: 2849–2859.

51. Ferrari LF, Bogen O, Green P, et al. Contribution of Piezo2 to endothelium-dependent pain. *Mol Pain* 2015; 11: 65.

52. Balonov K, Kodorova A and Strichartz GR. Tactile allodynia initiated by local subcutaneous endothelin-1 is prolonged by activation of TRPV-1 receptors. *Exp Biol Med (Maywood)* 2006; 231: 1165–1170.

53. Zhou Z, Davar G and Strichartz G. Endothelin-1 (ET-1) selectively enhances the activation gating of slowly inactivating tetrodotoxin-resistant sodium currents in rat sensory neurons: a mechanism for the pain-inducing actions of ET-1. *J Neurosci* 2002; 22: 6325–6330.

54. Plant TD, Zöllner C, Kepura F, et al. Endothelin potentiates TRPV1 via ET_{A} receptor-mediated activation of protein kinase C. *Mol Pain* 2007; 3: 35.

55. Zheng X, Tai Y, He D, et al. ET_{A}R and protein kinase A pathway mediate ET-1 sensitization of TRPA1 channel: a molecular mechanism of ET-1-induced mechanical hyperalgesia. *Mol Pain* 2019; 15: 1–11.

56. Khodorova A, Richter J, Vasko MR, et al. Early and late contributions of glutamate and CGRP to mechanical sensitization by endothelin-1. *J Pain* 2009; 10: 740–749.

57. Bae S, Matsunaga Y, Tanaka Y, et al. Autocrine induction of substance P mRNA and peptide in cultured normal human keratinocytes. *Biochem Biophys Res Commun* 1999; 263: 327–333.

58. Hou Q, Barr T, Gee L, et al. Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms. *Pain* 2011; 152: 2036–2051.

59. Ferrari LS, Green PG, Araldi D, et al. Sexual dimorphism in the contribution of neuroendocrine stress axes to oxaliplatin-induced painful peripheral neuropathy. *Pain* 2021; 162: 907–918.

60. Tostes RC, David FL, Carvalho MH, et al. Gender differences in vascular reactivity to endothelin-1 in deoxycorticosterone-salt hypertensive rats. *J Cardiovasc Pharmacol* 2000; 36: S99–S101.

61. Gohar EY, Cook AK, Pollock DM, et al. Afferent arteriole responsiveness to endothelin receptor activation: does sex matter? *Biol Sex Differ* 2019; 10: 1.